Judith Agudo
@JudithAgudo1
Immune evasion of stem cells and cancer stem cells. Mother of 3 boys. Tweets are my own.
Happy Halloween! Looking for some spooky reading? 👻 @JudithAgudo1 & @YMphoenix highlight the mechanisms through which normal #stemcells + #cancerstemcells achieve immune resistance (👻), offering insight for developing new cancer therapies. 👻📖👇 bit.ly/40nGGmk
Thrilled to share our latest review with @JudithAgudo1 on the unique immune resistance mechanisms of #CancerStemCells in solid tumors! Explore how these insights are reshaping cancer therapy approaches. #Immunology #CancerResearch #CancerImmunotherapy"
NEW content online! Stemness in solid malignancies: coping with immune attack go.nature.com/3AgxPrR
Proud to share @niseto’s (new PI @TheCrick) paper: As a postdoc (@CSHL/@HopkinsMedicine), he found #NETs in necrotic tumors—I shrugged. But he looked closer: NETs block tumor vessel perfusion, causing necrosis, hypoxia, EMT & #Metastasis. nature.com/articles/s4158… @JHU_BDP @Nature
Such an interesting and relevant finding explaining how the seeds of metastasis are gestated in the primary tumor by necrosis! Congrats!
Proud to share @niseto’s (new PI @TheCrick) paper: As a postdoc (@CSHL/@HopkinsMedicine), he found #NETs in necrotic tumors—I shrugged. But he looked closer: NETs block tumor vessel perfusion, causing necrosis, hypoxia, EMT & #Metastasis. nature.com/articles/s4158… @JHU_BDP @Nature
Stellar postdoc @DebolinaGanguly and I wrote this spotlight in for a super cool paper on the systemic effects of metatasis in breast cancer. The organ of metastatic disease has a BIG impact! Highly recommended paper in @Cancer_Cell secure-web.cisco.com/1be_LDSMLB9GnZ…
The deadliest cancers don’t just resist treatment, they vanish from the immune system’s view. PICI Investigator @JudithAgudo1, PhD, @DanaFarber has made it her mission to expose them. This week, that mission was recognized with the 2025 CRI Lloyd J. Old STAR Award, one of…
Thanks to the people in my lab, my mentors and collaborators. And the sources of funding that launched my lab @nyscf @DanaFarberNews @harvardmed @parkerici and the DoD breast cancer program.
So honored! Thanks to @CancerResearch for this recognition and amazing opportunity
So honored! Thanks to @CancerResearch for this recognition and amazing opportunity
🌟 Meet the 2025 Lloyd J. Old STARs- five extraordinary rising scientific leaders whose work is pushing the boundaries of what’s possible in cancer immunotherapy! Discover: bit.ly/4kFIjmo #CancerResearch #Immunotherapy (1/2)
.@Nature has just published pivotal findings on GD2-CAR T-cell therapy for childhood brain cancer – a novel therapy that recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. nature.com/articles/s4158… (1/3)
PICI applauds the FDA's decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation to the GD2-CAR T cell therapy for diffuse midline gliomas (DMG), devastating and almost always fatal pediatric cancers, with no approved therapies beyond palliative care. (1/3)
I haven’t posted much since Twitter is X, but I have a good reason today☺️ if you like #cancerstemcells #stemcells and #immunotherapy, this is for you! With partner in crime Phoenix Miao😎 nature.com/articles/s4156…
So proud of @debog93 for receiving this prestigious fellowship from @parkerici to discover how to make breast cancer responsive to immunotherapy. World, get ready, a new super star is rising!
PICI is thrilled to award over $1 million in total to our 2024 class of Early Career Researcher recipients. These bold investigators are propelling #immunotherapy w/ pioneering research that could lead to breakthrough discoveries. Meet the 2024 awardees: linkedin.com/feed/update/ur…
Very interesting data from @JudithAgudo1 showing new mechanisms for pan-immune cell evasion specific to metastasis #MRS2024 @MetastasisRS
PICI is thrilled to award over $1 million in total to our 2024 class of Early Career Researcher recipients. These bold investigators are propelling #immunotherapy w/ pioneering research that could lead to breakthrough discoveries. Meet the 2024 awardees: linkedin.com/feed/update/ur…
Really appreciate this thoughtful piece from @JudithAgudo1 and Shannon McCarthy on our recent @ImmunityCP paper! cell.com/immunity/fullt…
Happy to see this special issue on cancer as part of Cell’s #50YearsofCell celebration!
As part of the #50YearsofCell, our focus issue on Cancer is out! cell.com/cell/current In this issue, you'll find reviews, perspectives, and BenchMarks on the systemic complexity of cancer, and on some of the genes and proteins most intricately involved in the…
Excited to share that I'll be speaking at the upcoming Nature Conference on Cancer Immunotherapy: From Bench to Bedside and Back! Join us to discuss cutting-edge research in the field. go.nature.com/43Azhj2
This is why we made the JEDI mice, a tool for the broad immunology community☺️. So excited to see it helped for these cool findings on resistance of Tuft cells. And that ISCs are killed reproducing our @ImmunityCP paper!
Using JEDI mice developed by Brian Brown and @JudithAgudo1 we show that GFP-specific CD8s can kill GFP+ intestinal stem cells and erythroid precursors but tuft cells in the colon are relatively resistant to killing. 3/n
@JudithAgudo1’s lab is at #EACRTumorEcosystem2024 conference @EACRnews. Come check out our poster #20, 37, 53,60 and 79! Also Monica gives a talk tomorrow!
What an honor being featured at Cancer Discovery with @ohyilmaz and Nori Goto☺️ @DanaFarber @harvardmed @MIT
#ResearchWatch: SOX17 Mediates Immune Evasion During Early #ColonCancer Progression, a summary of the multidisciplinary and collaborative efforts of Norihiro Goto, @JudithAgudo1, @ohyilmaz et al. bit.ly/48LPEu9 @MITBiology @kochinstitute, @DanaFarber @BIMCpath @MGHpath
Wishing everyone a very happy International Women's Day! Please join us at the Women in Science Symposium on April 9, 2024 to celebrate some remarkable scientists of the greater Boston area. harvard.zoom.us/webinar/regist…